Litman Gregory Wealth Management LLC Buys 22,445 Shares of Zoetis Inc. $ZTS

Litman Gregory Wealth Management LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 289.2% in the third quarter, Holdings Channel.com reports. The firm owned 30,207 shares of the company’s stock after purchasing an additional 22,445 shares during the quarter. Litman Gregory Wealth Management LLC’s holdings in Zoetis were worth $4,420,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Scott & Selber Inc. raised its position in Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after buying an additional 67 shares during the last quarter. North Star Asset Management Inc. lifted its position in shares of Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after purchasing an additional 67 shares in the last quarter. Secure Asset Management LLC boosted its holdings in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares during the last quarter. Moment Partners LLC grew its position in Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares in the last quarter. Finally, CVA Family Office LLC increased its stake in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after buying an additional 74 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $126.16 on Friday. The stock has a market cap of $55.60 billion, a PE ratio of 21.24, a P/E/G ratio of 2.73 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The firm has a 50-day moving average of $127.05 and a 200-day moving average of $143.14. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio is 33.67%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Argus reissued a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.